Kyverna Therapeutics, Inc. KYTX
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Kyverna Therapeutics Inc. is a biotechnology company pioneering innovative therapeutics focusing on autoimmune diseases. Kyverna's primary goal is to harness cell therapies to target and suppress the immune system's harmful autoimmune responses. The company's unique approach lies in its development of engineered T cell…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees130
TickerKYTX
Statistics
Market Cap$484.6M
Revenue (TTM)$0
Net Income-$161.3M
Net Margin—
EPS$-3.64
P/E-2.16
P/S—
P/B2.43
EV/EBITDA-1.69
ROE-74.5%
Dividend Yield—
Price$8.01
Data: Twelve Data · Revenue = mcap / P/S